Last reviewed · How we verify
protein subunit: Novavax COVID-19 vaccine
protein subunit: Novavax COVID-19 vaccine is a Protein subunit vaccine Biologic drug developed by Novavax. It is currently FDA-approved for COVID-19 prevention in adults (primary series and booster doses). Also known as: 2024-25 COVID-19 vaccination.
The Novavax COVID-19 vaccine delivers recombinant SARS-CoV-2 spike protein nanoparticles with an adjuvant to stimulate immune responses against the virus.
The Novavax COVID-19 vaccine delivers recombinant SARS-CoV-2 spike protein nanoparticles with an adjuvant to stimulate immune responses against the virus. Used for COVID-19 prevention in adults (primary series and booster doses).
At a glance
| Generic name | protein subunit: Novavax COVID-19 vaccine |
|---|---|
| Also known as | 2024-25 COVID-19 vaccination |
| Sponsor | Novavax |
| Drug class | Protein subunit vaccine |
| Target | SARS-CoV-2 spike protein |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains recombinant spike protein produced in insect cells, formulated into nanoparticles and combined with Matrix-M adjuvant to enhance immunogenicity. This stimulates both cellular and humoral immune responses, enabling the body to recognize and neutralize SARS-CoV-2 upon exposure. Unlike mRNA vaccines, this is a protein subunit approach that does not require integration into host cells.
Approved indications
- COVID-19 prevention in adults (primary series and booster doses)
Common side effects
- Injection site pain
- Fatigue
- Myalgia
- Headache
- Fever
- Nausea
Key clinical trials
- COVID-19 Booster Study in Healthy Adults in Australia (PHASE3)
- Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States (PHASE4)
- COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- protein subunit: Novavax COVID-19 vaccine CI brief — competitive landscape report
- protein subunit: Novavax COVID-19 vaccine updates RSS · CI watch RSS
- Novavax portfolio CI
Frequently asked questions about protein subunit: Novavax COVID-19 vaccine
What is protein subunit: Novavax COVID-19 vaccine?
How does protein subunit: Novavax COVID-19 vaccine work?
What is protein subunit: Novavax COVID-19 vaccine used for?
Who makes protein subunit: Novavax COVID-19 vaccine?
Is protein subunit: Novavax COVID-19 vaccine also known as anything else?
What drug class is protein subunit: Novavax COVID-19 vaccine in?
What development phase is protein subunit: Novavax COVID-19 vaccine in?
What are the side effects of protein subunit: Novavax COVID-19 vaccine?
What does protein subunit: Novavax COVID-19 vaccine target?
Related
- Drug class: All Protein subunit vaccine drugs
- Target: All drugs targeting SARS-CoV-2 spike protein
- Manufacturer: Novavax — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for COVID-19 prevention in adults (primary series and booster doses)
- Also known as: 2024-25 COVID-19 vaccination
- Compare: protein subunit: Novavax COVID-19 vaccine vs similar drugs
- Pricing: protein subunit: Novavax COVID-19 vaccine cost, discount & access